The medtech association AdvaMed went to Capitol Hill today to make the case that the medical device industry should be exempt ...

Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate ...

Siemens Healthineers announced plans to relocate some of the manufacturing for its Varian radiotherapy division from Mexico ...

When it comes to training artificial intelligence, OpenAI and Babylon Biosciences have shown that experienced hands can help ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

Allogene Therapeutics is cutting back to stretch its cash runway into the second half of 2027, laying off 28% of its ...

Acelyrin’s shareholders have decided to power ahead with a planned merger with immune-mediated disease specialist Alumis, ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Kyverna Therapeutics may consider it had an “exceptional start to the year,” but that didn’t immunize the cell therapy ...

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work ...

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that ...